{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:54:58Z","timestamp":1794272098248,"version":"4.9.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute on Aging and the National Institute of Neurological Disorders and Stroke"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Netherlands Organization for Scientific Research","award":["024.004.012"],"award-info":[{"award-number":["024.004.012"]}]},{"name":"The Netherlands Organization for Scientific Research","award":["024.004.012"],"award-info":[{"award-number":["024.004.012"]}]},{"name":"National Institute Of Mental Health of the National Institutes of Health","award":["R01MH124873"],"award-info":[{"award-number":["R01MH124873"]}]},{"name":"National Institute Of Mental Health of the National Institutes of Health","award":["R01MH124873"],"award-info":[{"award-number":["R01MH124873"]}]},{"name":"National Institute Of Mental Health of the National Institutes of Health","award":["R01MH124873"],"award-info":[{"award-number":["R01MH124873"]}]},{"name":"National Institute Of Mental Health of the National Institutes of Health","award":["R01MH124873"],"award-info":[{"award-number":["R01MH124873"]}]},{"name":"European Union\u2019s Horizon program","award":["101057454, \u201cPsychSTRATA\u201d"],"award-info":[{"award-number":["101057454, \u201cPsychSTRATA\u201d"]}]},{"name":"European Union\u2019s Horizon program","award":["101057454, \u201cPsychSTRATA\u201d"],"award-info":[{"award-number":["101057454, \u201cPsychSTRATA\u201d"]}]},{"name":"European Union\u2019s Horizon program","award":["101057454, \u201cPsychSTRATA\u201d"],"award-info":[{"award-number":["101057454, \u201cPsychSTRATA\u201d"]}]},{"name":"The German Research Foundation","award":["402170461 \u201cTRR265\u201d"],"award-info":[{"award-number":["402170461 \u201cTRR265\u201d"]}]},{"name":"The German Research Foundation","award":["402170461 \u201cTRR265\u201d"],"award-info":[{"award-number":["402170461 \u201cTRR265\u201d"]}]},{"name":"German Center for Mental Health"},{"name":"The European Union\u2019s Horizon program","award":["964874, \u201cREALMENT\u201d"],"award-info":[{"award-number":["964874, \u201cREALMENT\u201d"]}]},{"name":"The European Union\u2019s Horizon program","award":["964874, \u201cREALMENT\u201d"],"award-info":[{"award-number":["964874, \u201cREALMENT\u201d"]}]},{"name":"The European Research Council","award":["ERC-2018-AdG GWAS2FUNC 834057"],"award-info":[{"award-number":["ERC-2018-AdG GWAS2FUNC 834057"]}]},{"name":"The Alexander von Humboldt Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Many drug targets in ongoing Parkinson\u2019s disease (PD) clinical trials have strong genetic links. While genome-wide association studies (GWAS) nominate regions associated with disease, pinpointing causal genes is challenging. Our aim was to prioritize additional druggable genes underlying PD GWAS signals. The polygenic priority score (PoPS) integrates genome-wide information from MAGMA gene-level associations and over 57,000 gene-level features. We applied PoPS to East Asian and European PD GWAS data and prioritized genes based on PoPS, distance to the GWAS signal, and non-synonymous credible set variants. We prioritized 46 genes, including well-established PD genes (\n                    <jats:italic>SNCA<\/jats:italic>\n                    ,\n                    <jats:italic>LRRK2<\/jats:italic>\n                    ,\n                    <jats:italic>GBA1<\/jats:italic>\n                    ,\n                    <jats:italic>TMEM175<\/jats:italic>\n                    ,\n                    <jats:italic>VPS13C<\/jats:italic>\n                    ), genes with strong literature evidence supporting a mechanistic link to PD (\n                    <jats:italic>RIT2, BAG3<\/jats:italic>\n                    ,\n                    <jats:italic>SCARB2, FYN, DYRK1A, NOD2, CTSB, SV2C, ITPKB<\/jats:italic>\n                    ), and genes relatively unexplored in PD. Many hold potential for drug repurposing or development. We prioritized high-confidence genes with strong links to PD pathogenesis that may represent our next-best candidates for developing disease-modifying therapeutics.\n                  <\/jats:p>","DOI":"10.1038\/s41531-025-00933-0","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T10:40:24Z","timestamp":1744800024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Prioritizing Parkinson\u2019s disease risk genes in genome-wide association loci"],"prefix":"10.1038","volume":"11","author":[{"given":"Lara M.","family":"Lange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Cerquera-Cleves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijn","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Panagiotaropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Posthuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ripke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Blauwendraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Heilbron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"933_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"GBD 2016 Parkinson\u2019s Disease Collaborators.","year":"2018","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators. Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 939\u2013953 (2018).","journal-title":"Lancet Neurol."},{"key":"933_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.26467","volume":"92","author":"MT Peri\u00f1\u00e1n","year":"2022","unstructured":"Peri\u00f1\u00e1n, M. T. et al. Effect modification between genes and environment and Parkinson\u2019s disease risk. Ann. Neurol. 92, 715\u2013724 (2022).","journal-title":"Ann. Neurol."},{"key":"933_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.tins.2023.03.009","volume":"46","author":"W-J Neumann","year":"2023","unstructured":"Neumann, W.-J., Horn, A. & K\u00fchn, A. A. Insights and opportunities for deep brain stimulation as a brain circuit intervention. Trends Neurosci. 46, 472\u2013487 (2023).","journal-title":"Trends Neurosci."},{"key":"933_CR4","doi-asserted-by":"publisher","first-page":"e00348","DOI":"10.1016\/j.neurot.2024.e00348","volume":"21","author":"B Davidson","year":"2024","unstructured":"Davidson, B., Milosevic, L., Kondrataviciute, L., Kalia, L. V. & Kalia, S. K. Neuroscience fundamentals relevant to neuromodulation: Neurobiology of deep brain stimulation in Parkinson\u2019s disease. Neurotherapeutics 21, e00348 (2024).","journal-title":"Neurotherapeutics"},{"key":"933_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3233\/JPD-239901","volume":"13","author":"K McFarthing","year":"2023","unstructured":"McFarthing, K. et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2023 update. J. Parkinsons. Dis. 13, 427\u2013439 (2023).","journal-title":"J. Parkinsons. Dis."},{"key":"933_CR6","doi-asserted-by":"publisher","unstructured":"Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic evidence on clinical success. Nature https:\/\/doi.org\/10.1038\/s41586-024-07316-0 (2024).","DOI":"10.1038\/s41586-024-07316-0"},{"key":"933_CR7","doi-asserted-by":"publisher","first-page":"e1008489","DOI":"10.1371\/journal.pgen.1008489","volume":"15","author":"EA King","year":"2019","unstructured":"King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet 15, e1008489 (2019).","journal-title":"PLoS Genet"},{"key":"933_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/d41573-022-00120-3","volume":"21","author":"D Ochoa","year":"2022","unstructured":"Ochoa, D. et al. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat. Rev. Drug Discov. 21, 551 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"933_CR9","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/d41573-023-00158-x","volume":"22","author":"PV Rusina","year":"2023","unstructured":"Rusina, P. V. et al. Genetic support for FDA-approved drugs over the past decade. Nat. Rev. Drug Discov. 22, 864 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"933_CR10","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856\u2013860 (2015).","journal-title":"Nat. Genet."},{"key":"933_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrd4692","volume":"14","author":"M Cully","year":"2015","unstructured":"Cully, M. Genetic information adds supporting weight. Nat. Rev. Drug Discov. 14, 525\u2013525 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"933_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/ana.26905","volume":"95","author":"M Khani","year":"2024","unstructured":"Khani, M. et al. Towards a Global View of Parkinson\u2019s Disease Genetics. Ann. Neurol. 95, 831\u2013842 (2024).","journal-title":"Ann. Neurol."},{"key":"933_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091\u20131102 (2019).","journal-title":"Lancet Neurol."},{"key":"933_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/ana.26153","volume":"90","author":"DP Loesch","year":"2021","unstructured":"Loesch, D. P. et al. Characterizing the genetic architecture of Parkinson\u2019s disease in Latinos. Ann. Neurol. 90, 353\u2013365 (2021).","journal-title":"Ann. Neurol."},{"key":"933_CR15","first-page":"226","volume":"26","author":"JN Foo","year":"2017","unstructured":"Foo, J. N. et al. Genome-wide association study of Parkinson\u2019s disease in East Asians. Hum. Mol. Genet. 26, 226\u2013232 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"933_CR16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaneurol.2020.0428","volume":"77","author":"JN Foo","year":"2020","unstructured":"Foo, J. N. et al. Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans: A Genome-Wide Association Study. JAMA Neurol. 77, 746\u2013754 (2020).","journal-title":"JAMA Neurol."},{"key":"933_CR17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(23)00283-1","volume":"22","author":"M Rizig","year":"2023","unstructured":"Rizig, M. et al. Identification of genetic risk loci and causal insights associated with Parkinson\u2019s disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 22, 1015\u20131025 (2023).","journal-title":"Lancet Neurol."},{"key":"933_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41588-023-01584-8","volume":"56","author":"JJ Kim","year":"2024","unstructured":"Kim, J. J. et al. Multi-ancestry genome-wide association meta-analysis of Parkinson\u2019s disease. Nat. Genet. 56, 27\u201336 (2024).","journal-title":"Nat. Genet."},{"key":"933_CR19","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s41588-023-01443-6","volume":"55","author":"EM Weeks","year":"2023","unstructured":"Weeks, E. M. et al. Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases. Nat. Genet. 55, 1267\u20131276 (2023).","journal-title":"Nat. Genet."},{"key":"933_CR20","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41588-021-00945-5","volume":"53","author":"E Mountjoy","year":"2021","unstructured":"Mountjoy, E. et al. An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. Nat. Genet. 53, 1527\u20131533 (2021).","journal-title":"Nat. Genet."},{"key":"933_CR21","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/brain\/awad345","volume":"147","author":"E Yu","year":"2024","unstructured":"Yu, E. et al. Machine learning nominates the inositol pathway and novel genes in Parkinson\u2019s disease. Brain 147, 887\u2013899 (2024).","journal-title":"Brain"},{"key":"933_CR22","doi-asserted-by":"publisher","first-page":"e1004219","DOI":"10.1371\/journal.pcbi.1004219","volume":"11","author":"CA de Leeuw","year":"2015","unstructured":"de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 11, e1004219 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"933_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","volume":"22","author":"N Giladi","year":"2023","unstructured":"Giladi, N. et al. Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 22, 661\u2013671 (2023).","journal-title":"Lancet Neurol."},{"key":"933_CR24","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/mds.29346","volume":"38","author":"JM den Heijer","year":"2023","unstructured":"den Heijer, J. M. et al. A phase 1B trial in GBA1-associated parkinson\u2019s disease of BIA-28-6156, a glucocerebrosidase activator. Mov. Disord. 38, 1197\u20131208 (2023).","journal-title":"Mov. Disord."},{"key":"933_CR25","doi-asserted-by":"publisher","first-page":"705407","DOI":"10.3389\/fneur.2021.705407","volume":"12","author":"G Pagano","year":"2021","unstructured":"Pagano, G. et al. A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson\u2019s disease (PASADENA): Rationale, design, and baseline data. Front. Neurol. 12, 705407 (2021).","journal-title":"Front. Neurol."},{"key":"933_CR26","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/mds.27738","volume":"34","author":"M Brys","year":"2019","unstructured":"Brys, M. et al. Randomized phase I clinical trial of anti-\u03b1-synuclein antibody BIIB054. Mov. Disord. 34, 1154\u20131163 (2019).","journal-title":"Mov. Disord."},{"key":"933_CR27","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang, A. E. et al. Trial of cinpanemab in early Parkinson\u2019s disease. N. Engl. J. Med. 387, 408\u2013420 (2022).","journal-title":"N. Engl. J. Med."},{"key":"933_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34490-9","volume":"8","author":"DL Price","year":"2018","unstructured":"Price, D. L. et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease. Sci. Rep. 8, 16165 (2018).","journal-title":"Sci. Rep."},{"key":"933_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","volume":"77","author":"FL Pagan","year":"2020","unstructured":"Pagan, F. L. et al. Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: A phase 2 randomized clinical trial. JAMA Neurol. 77, 309\u2013317 (2020).","journal-title":"JAMA Neurol."},{"key":"933_CR30","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1093\/hmg\/ddz136","volume":"28","author":"S Jinn","year":"2019","unstructured":"Jinn, S. et al. Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease. Hum. Mol. Genet. 28, 3244\u20133254 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"933_CR31","first-page":"3974","volume":"27","author":"T Uenaka","year":"2018","unstructured":"Uenaka, T. et al. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson\u2019s disease. Hum. Mol. Genet. 27, 3974\u20133985 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"933_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41531-023-00484-2","volume":"9","author":"J Obergasteiger","year":"2023","unstructured":"Obergasteiger, J. et al. The small GTPase Rit2 modulates LRRK2 kinase activity, is required for lysosomal function and protects against alpha-synuclein neuropathology. NPJ Parkinsons Dis. 9, 44 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"933_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41531-024-00648-8","volume":"10","author":"PJ Kearney","year":"2024","unstructured":"Kearney, P. J. et al. Silencing Parkinson\u2019s risk allele Rit2 sex-specifically compromises motor function and dopamine neuron viability. NPJ Parkinsons Dis. 10, 41 (2024).","journal-title":"NPJ Parkinsons Dis."},{"key":"933_CR34","doi-asserted-by":"publisher","first-page":"105482","DOI":"10.1016\/j.nbd.2021.105482","volume":"159","author":"AL Olsen","year":"2021","unstructured":"Olsen, A. L. & Feany, M. B. Parkinson\u2019s disease risk genes act in glia to control neuronal \u03b1-synuclein toxicity. Neurobiol. Dis. 159, 105482 (2021).","journal-title":"Neurobiol. Dis."},{"key":"933_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adi8287","volume":"10","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. Molecular profiling of human substantia nigra identifies diverse neuron types associated with vulnerability in Parkinson\u2019s disease. Sci. Adv. 10, eadi8287 (2024).","journal-title":"Sci. Adv."},{"key":"933_CR36","doi-asserted-by":"publisher","first-page":"9098","DOI":"10.3390\/ijms22169098","volume":"22","author":"S Demuro","year":"2021","unstructured":"Demuro, S., Di Martino, R. M. C., Ortega, J. A. & Cavalli, A. GSK-3\u03b2, FYN, and DYRK1A: Master regulators in neurodegenerative pathways. Int. J. Mol. Sci. 22, 9098 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"933_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.pharmthera.2018.09.010","volume":"194","author":"ML Arbones","year":"2019","unstructured":"Arbones, M. L., Thomazeau, A., Nakano-Kobayashi, A., Hagiwara, M. & Delabar, J. M. DYRK1A and cognition: A lifelong relationship. Pharmacol. Ther. 194, 199\u2013221 (2019).","journal-title":"Pharmacol. Ther."},{"key":"933_CR38","doi-asserted-by":"publisher","first-page":"33250","DOI":"10.1074\/jbc.M606147200","volume":"281","author":"EJ Kim","year":"2006","unstructured":"Kim, E. J. et al. Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. J. Biol. Chem. 281, 33250\u201333257 (2006).","journal-title":"J. Biol. Chem."},{"key":"933_CR39","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/jnc.13164","volume":"134","author":"E Im","year":"2015","unstructured":"Im, E. & Chung, K. C. Dyrk1A phosphorylates parkin at Ser-131 and negatively regulates its ubiquitin E3 ligase activity. J. Neurochem. 134, 756\u2013768 (2015).","journal-title":"J. Neurochem."},{"key":"933_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neurobiolaging.2017.08.023","volume":"60","author":"Y-L Cao","year":"2017","unstructured":"Cao, Y.-L. et al. A role of BAG3 in regulating SNCA\/\u03b1-synuclein clearance via selective macroautophagy. Neurobiol. Aging 60, 104\u2013115 (2017).","journal-title":"Neurobiol. Aging"},{"key":"933_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2990.2011.01198.x","volume":"38","author":"K Seidel","year":"2012","unstructured":"Seidel, K. et al. The HSPB8-BAG3 chaperone complex is upregulated in astrocytes in the human brain affected by protein aggregation diseases. Neuropathol. Appl. Neurobiol. 38, 39\u201353 (2012).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"933_CR42","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.neuron.2023.05.006","volume":"111","author":"PW Sheehan","year":"2023","unstructured":"Sheehan, P. W. et al. An astrocyte BMAL1-BAG3 axis protects against alpha-synuclein and tau pathology. Neuron 111, 2383\u20132398.e7 (2023).","journal-title":"Neuron"},{"key":"933_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40035-018-0143-7","volume":"8","author":"S-Z Lu","year":"2019","unstructured":"Lu, S.-Z. et al. Suppression of astrocytic autophagy by \u03b1B-crystallin contributes to \u03b1-synuclein inclusion formation. Transl. Neurodegener. 8, 3 (2019).","journal-title":"Transl. Neurodegener."},{"key":"933_CR44","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.21037\/atm-22-5159","volume":"10","author":"Z-M Ying","year":"2022","unstructured":"Ying, Z.-M. et al. BAG3 promotes autophagy and suppresses NLRP3 inflammasome activation in Parkinson\u2019s disease. Ann. Transl. Med 10, 1218 (2022).","journal-title":"Ann. Transl. Med"},{"key":"933_CR45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s42003-020-0804-9","volume":"3","author":"A Keo","year":"2020","unstructured":"Keo, A. et al. Transcriptomic signatures of brain regional vulnerability to Parkinson\u2019s disease. Commun. Biol. 3, 101 (2020).","journal-title":"Commun. Biol."},{"key":"933_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-020-00712-3","volume":"14","author":"R Thomas","year":"2021","unstructured":"Thomas, R., Moloney, E. B., Macbain, Z. K., Hallett, P. J. & Isacson, O. Fibroblasts from idiopathic Parkinson\u2019s disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2. Mol. Brain 14, 16 (2021).","journal-title":"Mol. Brain"},{"key":"933_CR47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.neulet.2019.05.034","volume":"706","author":"L P\u00e9rez-Roca","year":"2019","unstructured":"P\u00e9rez-Roca, L. et al. Glucocerebrosidase regulators SCARB2 and TFEB are up-regulated in Lewy body disease brain. Neurosci. Lett. 706, 164\u2013168 (2019).","journal-title":"Neurosci. Lett."},{"key":"933_CR48","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1073\/pnas.1514005113","volume":"113","author":"F Zunke","year":"2016","unstructured":"Zunke, F. et al. Characterization of the complex formed by \u03b2-glucocerebrosidase and the lysosomal integral membrane protein type-2. Proc. Natl. Acad. Sci. USA 113, 3791\u20133796 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"933_CR49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","volume":"82","author":"G Ambrosi","year":"2015","unstructured":"Ambrosi, G. et al. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson\u2019s disease cells. Neurobiol. Dis. 82, 235\u2013242 (2015).","journal-title":"Neurobiol. Dis."},{"key":"933_CR50","doi-asserted-by":"publisher","first-page":"129674","DOI":"10.1016\/j.bmcl.2024.129674","volume":"102","author":"R Kohal","year":"2024","unstructured":"Kohal, R. et al. Fyn, Blk, and Lyn kinase inhibitors: A mini-review on medicinal attributes, research progress, and future insights. Bioorg. Med. Chem. Lett. 102, 129674 (2024).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"933_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03930-0","volume":"21","author":"S Peng","year":"2023","unstructured":"Peng, S. & Fu, Y. FYN: emerging biological roles and potential therapeutic targets in cancer. J. Transl. Med. 21, 84 (2023).","journal-title":"J. Transl. Med."},{"key":"933_CR52","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.3390\/ijms25084565","volume":"25","author":"R Ramos","year":"2024","unstructured":"Ramos, R. & Vale, N. Dual drug repurposing: The example of saracatinib. Int. J. Mol. Sci. 25, 4565 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"933_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13195-015-0119-0","volume":"7","author":"HB Nygaard","year":"2015","unstructured":"Nygaard, H. B. et al. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer\u2019s disease. Alzheimers Res. Ther. 7, 35 (2015).","journal-title":"Alzheimers Res. Ther."},{"key":"933_CR54","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","volume":"76","author":"CH van Dyck","year":"2019","unstructured":"van Dyck, C. H. et al. Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: A randomized clinical trial. JAMA Neurol. 76, 1219\u20131229 (2019).","journal-title":"JAMA Neurol."},{"key":"933_CR55","doi-asserted-by":"publisher","first-page":"10058","DOI":"10.1523\/JNEUROSCI.0302-15.2015","volume":"35","author":"N Panicker","year":"2015","unstructured":"Panicker, N. et al. Fyn kinase regulates microglial neuroinflammatory responses in cell culture and animal models of Parkinson\u2019s disease. J. Neurosci. 35, 10058\u201310077 (2015).","journal-title":"J. Neurosci."},{"key":"933_CR56","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1084\/jem.20182191","volume":"216","author":"N Panicker","year":"2019","unstructured":"Panicker, N. et al. Fyn kinase regulates misfolded \u03b1-synuclein uptake and NLRP3 inflammasome activation in microglia. J. Exp. Med. 216, 1411\u20131430 (2019).","journal-title":"J. Exp. Med."},{"key":"933_CR57","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/bpa.12917","volume":"31","author":"CYB Low","year":"2021","unstructured":"Low, C. Y. B. et al. Isoform-specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer\u2019s disease and Lewy body dementias. Brain Pathol. 31, 253\u2013266 (2021).","journal-title":"Brain Pathol."},{"key":"933_CR58","doi-asserted-by":"publisher","first-page":"5125","DOI":"10.1007\/s12035-017-0748-3","volume":"55","author":"S Sanz-Blasco","year":"2018","unstructured":"Sanz-Blasco, S. et al. The kinase Fyn as a novel intermediate in L-DOPA-induced dyskinesia in Parkinson\u2019s disease. Mol. Neurobiol. 55, 5125\u20135136 (2018).","journal-title":"Mol. Neurobiol."},{"key":"933_CR59","doi-asserted-by":"publisher","first-page":"173259","DOI":"10.1016\/j.ejphar.2020.173259","volume":"881","author":"H Saminathan","year":"2020","unstructured":"Saminathan, H. et al. Fyn kinase mediates pro-inflammatory response in a mouse model of endotoxemia: Relevance to translational research. Eur. J. Pharmacol. 881, 173259 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"933_CR60","doi-asserted-by":"publisher","first-page":"631375","DOI":"10.3389\/fphar.2021.631375","volume":"12","author":"H Saminathan","year":"2021","unstructured":"Saminathan, H. et al. Fyn kinase-mediated PKC\u03b4 Y311 phosphorylation induces dopaminergic degeneration in cell culture and animal models: Implications for the identification of a new pharmacological target for Parkinson\u2019s disease. Front. Pharmacol. 12, 631375 (2021).","journal-title":"Front. Pharmacol."},{"key":"933_CR61","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ejmech.2018.08.093","volume":"158","author":"A Pathak","year":"2018","unstructured":"Pathak, A. et al. DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective. Eur. J. Med. Chem. 158, 559\u2013592 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"933_CR62","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/13543776.2017.1360285","volume":"27","author":"TL Nguyen","year":"2017","unstructured":"Nguyen, T. L., Fruit, C., H\u00e9rault, Y., Meijer, L. & Besson, T. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature. Expert Opin. Ther. Pat. 27, 1183\u20131199 (2017).","journal-title":"Expert Opin. Ther. Pat."},{"key":"933_CR63","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/brainsci8100187","volume":"8","author":"A Feki","year":"2018","unstructured":"Feki, A. & Hibaoui, Y. DYRK1A protein, a promising therapeutic target to improve cognitive deficits in down syndrome. Brain Sci. 8, 187 (2018).","journal-title":"Brain Sci."},{"key":"933_CR64","doi-asserted-by":"publisher","first-page":"9791","DOI":"10.1021\/acs.jmedchem.8b00185","volume":"61","author":"DB Jarhad","year":"2018","unstructured":"Jarhad, D. B., Mashelkar, K. K., Kim, H.-R., Noh, M. & Jeong, L. S. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics. J. Med. Chem. 61, 9791\u20139810 (2018).","journal-title":"J. Med. Chem."},{"key":"933_CR65","first-page":"8848642","volume":"2023","author":"Y Yong","year":"2023","unstructured":"Yong, Y. et al. Dyrk1a phosphorylation of \u03b1-synuclein mediating apoptosis of dopaminergic neurons in Parkinson\u2019s disease. Parkinsons Dis. 2023, 8848642 (2023).","journal-title":"Parkinsons Dis."},{"key":"933_CR66","doi-asserted-by":"publisher","unstructured":"Jones-Tabah, J. et al. The Parkinson\u2019s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-3979098\/v1 (2024).","DOI":"10.21203\/rs.3.rs-3979098\/v1"},{"key":"933_CR67","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1093\/hmg\/ddac047","volume":"31","author":"MJ Kim","year":"2022","unstructured":"Kim, M. J., Jeong, H. & Krainc, D. Lysosomal ceramides regulate cathepsin B-mediated processing of saposin C and glucocerebrosidase activity. Hum. Mol. Genet. 31, 2424\u20132437 (2022).","journal-title":"Hum. Mol. Genet."},{"key":"933_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40035-023-00363-z","volume":"12","author":"A Drobny","year":"2023","unstructured":"Drobny, A. et al. Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models. Transl. Neurodegener. 12, 31 (2023).","journal-title":"Transl. Neurodegener."},{"key":"933_CR69","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/d41573-021-00168-7","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard, A. The FDA approves a first farnesyltransferase inhibitor. Nat. Rev. Drug Discov. 20, 8 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"933_CR70","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/11204910-000000000-00000","volume":"12","author":"JE Frampton","year":"2010","unstructured":"Frampton, J. E. Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr. Drugs 12, 141\u2013153 (2010).","journal-title":"Paediatr. Drugs"},{"key":"933_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1289-z","volume":"15","author":"L Cheng","year":"2018","unstructured":"Cheng, L. et al. NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson\u2019s disease. J. Neuroinflamm. 15, 243 (2018).","journal-title":"J. Neuroinflamm."},{"key":"933_CR72","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.brainres.2010.09.063","volume":"1367","author":"D Dardou","year":"2011","unstructured":"Dardou, D. et al. Distribution of SV2C mRNA and protein expression in the mouse brain with a particular emphasis on the basal ganglia system. Brain Res. 1367, 130\u2013145 (2011).","journal-title":"Brain Res."},{"key":"933_CR73","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1111\/ejn.16311","volume":"59","author":"ML Bucher","year":"2024","unstructured":"Bucher, M. L. et al. Synaptic vesicle glycoprotein 2C enhances vesicular storage of dopamine and counters dopaminergic toxicity. Eur. J. Neurosci. 59, 2483\u20132501 (2024).","journal-title":"Eur. J. Neurosci."},{"key":"933_CR74","doi-asserted-by":"publisher","first-page":"E2253","DOI":"10.1073\/pnas.1616892114","volume":"114","author":"AR Dunn","year":"2017","unstructured":"Dunn, A. R. et al. Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc. Natl. Acad. Sci. USA 114, E2253\u2013E2262 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"933_CR75","doi-asserted-by":"publisher","first-page":"742625","DOI":"10.3389\/fneur.2021.742625","volume":"12","author":"G Kovacs","year":"2021","unstructured":"Kovacs, G., Reimer, L. & Jensen, P. H. Endoplasmic reticulum-based calcium dysfunctions in synucleinopathies. Front. Neurol. 12, 742625 (2021).","journal-title":"Front. Neurol."},{"key":"933_CR76","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.3390\/ijms24031984","volume":"24","author":"F Di Leva","year":"2023","unstructured":"Di Leva, F. et al. Increased levels of the Parkinson's disease-associated gene ITPKB correlate with higher expression levels of \u00e0-synuclein, independent of mutation status. Int. J. Mol. Sci. 24, 1984 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"933_CR77","doi-asserted-by":"publisher","first-page":"e2006476118","DOI":"10.1073\/pnas.2006476118","volume":"118","author":"DJ Apicco","year":"2021","unstructured":"Apicco, D. J. et al. The Parkinson's disease-associated gene ITPKB protects against \u03b1-synuclein aggregation by regulating ER-to-mitochondria calcium release. Proc. Natl. Acad. Sci. USA. 118, e2006476118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"933_CR78","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2021","unstructured":"Azmi, A. S., Uddin, M. H. & Mohammad, R. M. The nuclear export protein XPO1 - from biology to targeted therapy. Nat. Rev. Clin. Oncol. 18, 152\u2013169 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"933_CR79","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929\u20131940 (2019).","journal-title":"N. Engl. J. Med."},{"key":"933_CR80","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","volume":"49","author":"D Chang","year":"2017","unstructured":"Chang, D. et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci. Nat. Genet. 49, 1511\u20131516 (2017).","journal-title":"Nat. Genet."},{"key":"933_CR81","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1502214","volume":"373","author":"M Claussnitzer","year":"2015","unstructured":"Claussnitzer, M. et al. FTO obesity variant circuitry and adipocyte browning in humans. N. Engl. J. Med. 373, 895\u2013907 (2015).","journal-title":"N. Engl. J. Med."},{"key":"933_CR82","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1093\/bioinformatics\/btq340","volume":"26","author":"CJ Willer","year":"2010","unstructured":"Willer, C. J., Li, Y. & Abecasis, G. R. METAL: Fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190\u20132191 (2010).","journal-title":"Bioinformatics"},{"key":"933_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang, C. C. et al. Second-generation PLINK: Rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).","journal-title":"Gigascience"},{"key":"933_CR84","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/ng.2213","volume":"44","author":"J Yang","year":"2012","unstructured":"Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat. Genet. 44, 369\u2013375 (2012).","journal-title":"Nat. Genet."},{"key":"933_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"C Giambartolomei","year":"2014","unstructured":"Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet 10, e1004383 (2014).","journal-title":"PLoS Genet"},{"key":"933_CR86","doi-asserted-by":"publisher","first-page":"e1008720","DOI":"10.1371\/journal.pgen.1008720","volume":"16","author":"C Wallace","year":"2020","unstructured":"Wallace, C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLoS Genet 16, e1008720 (2020).","journal-title":"PLoS Genet"},{"key":"933_CR87","doi-asserted-by":"publisher","first-page":"D766","DOI":"10.1093\/nar\/gky955","volume":"47","author":"A Frankish","year":"2019","unstructured":"Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 47, D766\u2013D773 (2019).","journal-title":"Nucleic Acids Res"},{"key":"933_CR88","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/s41588-020-00735-5","volume":"52","author":"O Weissbrod","year":"2020","unstructured":"Weissbrod, O. et al. Functionally informed fine-mapping and polygenic localization of complex trait heritability. Nat. Genet. 52, 1355\u20131363 (2020).","journal-title":"Nat. Genet."},{"key":"933_CR89","doi-asserted-by":"publisher","first-page":"D985","DOI":"10.1093\/nar\/gkw1055","volume":"45","author":"G Koscielny","year":"2017","unstructured":"Koscielny, G. et al. Open Targets: a platform for therapeutic target identification and validation. Nucleic Acids Res. 45, D985\u2013D994 (2017).","journal-title":"Nucleic Acids Res."},{"key":"933_CR90","doi-asserted-by":"publisher","first-page":"eaag1166","DOI":"10.1126\/scitranslmed.aag1166","volume":"9","author":"C Finan","year":"2017","unstructured":"Finan, C. et al. The druggable genome and support for target identification and validation in drug development. Sci. Transl. Med. 9, eaag1166 (2017).","journal-title":"Sci. Transl. Med."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00933-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00933-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00933-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T16:03:40Z","timestamp":1744819420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00933-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["933"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-00933-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.13.24318996","asserted-by":"object"}]},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.H. is a former employee of 23andMe, Inc. and a current employee of Bayer AG. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}